CDK4 and non-small cell lung carcinoma: PAQR4 is also involved in the malignant ability of NSCLC through the CDK4-pRB-E2F1 pathway and can promote chemotherapy resistance in NSCLC by inhibiting Nrf2 protein degradation [12].